GGrantIndex
Sort

11,323 grants matching glioblastoma

Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody

$444,583
Wen Jiang · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · NS

Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.

$444,533
Alexander H. Stegh · Washington University · R01 · FY2024 · CA

Project 2: Deciphering the Dynamic Evolution of the Tumor-Immune Interface

$444,255
Stefani Spranger · Massachusetts Institute Of Technology · U54 · FY2025 · CA

Patterned optogenetic neuromodulation to reprogram glioma stem cells

$444,125
Robert C Rostomily · Methodist Hospital Research Institute · R21 · FY2024 · NS

Radiogenomics framework for non-invasive personalized medicine

$444,001
Olivier Gevaert · Stanford University · R56 · FY2019 · EB

Delineating microglial NF-kappaB signaling in glioblastoma growth and therapy

$443,996
Jennifer Webster Bradford · Augusta University · R15 · FY2019 · NS

Mechanism of regulation of progenitor proliferation and transformation

$443,782
Patrizia Casaccia · Advanced Science Research Center · R01 · FY2017 · NS

Hematopoietic Chemoprotection in Glioblastoma Patients

$443,776
Hans-Peter Kiem · Fred Hutchinson Cancer Research Center · R01 · FY2008 · CA

Identification and modeling of driver genetic modules in glioblastoma

$443,694
Antonio Iavarone · Columbia University Health Sciences · R01 · FY2018 · CA

Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies

$443,645
Maria G Castro · University Of Michigan At Ann Arbor · R37 · FY2021 · NS

Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies

$443,645
Maria G Castro · University Of Michigan At Ann Arbor · R37 · FY2019 · NS

Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies

$443,645
Maria G Castro · University Of Michigan At Ann Arbor · R37 · FY2020 · NS

The Role of Cellular Receptors Involved in Inflammation and Tumor Progression

$443,620
Ji Ming Wang · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Novel L-threo-sphinganines for ceramides-based cancer therapy

$443,579
Barry J Maurer · Texas Tech University Health Scis Center · R15 · FY2012 · CA

Immobilized Drug Transporters

$443,566
Irving William Wainer · National Institute On Aging · ZIA · FY2011 · AG

Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.

$443,482
Alexander H. Stegh · Washington University · R01 · FY2022 · CA

A Pathway of Tumor Suppression

$443,233
Guillermina Lozano · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Monoclonal Antibody to FGF2 for Treatment of Hepatocellular Carcinoma and Other C

$443,212
K Jin Kim · Galaxy Biotech, Llc · R44 · FY2011 · CA

Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.

$442,928
Erwin G Van Meir · University Of Alabama At Birmingham · R01 · FY2021 · NS

Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.

$442,928
Erwin G Van Meir · University Of Alabama At Birmingham · R01 · FY2022 · NS

Therapeutic Targeting of WDR5 in the Glioblastoma Perivascular Niche

$442,887
Christopher G Hubert · Case Western Reserve University · R01 · FY2024 · NS

Transcriptional Control of Human Cytomegalovirus Latency

$442,788
Robert F Kalejta · University Of Wisconsin-Madison · R01 · FY2025 · AI

Immobilized Drug Transporters

$442,785
Irving William Wainer · National Institute On Aging · ZIA · FY2013 · AG

Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?

$442,750
David M. Ashley · Duke University · R21 · FY2019 · NS

Induce and Image extrachromosomal DNA in human glioblastoma avatar

$442,750
Liangqi Xie · Cleveland Clinic Lerner Com-Cwru · R21 · FY2025 · NS